Daily patient-reported health status assessment improvements with benralizumab for patients with severe, uncontrolled eosinophilic asthma
Sean O’Quinn, Xiao Xu, Ian Hirsch AstraZeneca, Gaithersburg, MD, USA Background: Patients with severe, uncontrolled asthma experience debilitating symptoms that result in meaningful reductions to health-related quality of life. Benralizumab is an interleukin-5 receptor alpha–dire...
Main Authors: | O'Quinn S, Xu X, Hirsch I |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2019-01-01
|
Series: | Journal of Asthma and Allergy |
Subjects: | |
Online Access: | https://www.dovepress.com/daily-patient-reported-health-status-assessment-improvements-with-benr-peer-reviewed-article-JAA |
Similar Items
-
Patient-Reported Outcomes with Benralizumab in Patients with Severe Eosinophilic Asthma and Severe Chronic Rhinosinusitis with Nasal Polyps
by: Rory Chan, et al.
Published: (2023-03-01) -
Treatment of Widespread Eosinophilic Cellulitis (Wells’ Syndrome) with Benralizumab
by: Maria Blomberg, et al.
Published: (2020-11-01) -
Benralizumab use in chronic eosinophilic pneumonia with eosinophilic bronchiolitis and chronic airway infection
by: Tomotsugu Takano, et al.
Published: (2021-08-01) -
Successful treatment of eosinophilic cystitis with benralizumab
by: W Donald Cooke, et al.
Published: (2020-11-01) -
Rapid onset of effect of benralizumab in a severe eosinophilic and allergic asthma patient with allergic bronchopulmonary aspergillosis
by: Arvindran Alaga, et al.
Published: (2023-06-01)